Vimarsana
Biggest News Aggregation in the World

Formosa Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Formosa Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Formosa Pharma Today - Breaking & Trending Today

Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery - Vimarsana News

Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with...

Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery - Vimarsana News

Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with...

Eyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market Place (EYEN) - Vimarsana News

Eyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market Place (EYEN)

FDA gave approval of their first drug on May 8th, 2023. The company is now finalizing its drug launch in the coming months. Click here to read more on EYEN stock.

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia - Vimarsana News

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a collaboration agreement with...

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery. - Vimarsana News

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery.

/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the...